Mirza, M., Ghamande, S., Hanker, L., Black, D., Raascou-Jensen, N., Gilbert, L., … Powell, M. (2024). Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. In Gynecologic Oncology (Vol. 190, pp. S6–S6). Elsevier BV. https://doi.org/10.1016/j.ygyno.2024.07.016

Mirza, Mansoor, Sharad Ghamande, Lars Hanker, Destin Black, Nicoline Raascou-Jensen, Lucy Gilbert, Ana Oaknin, et al. “Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.” In Gynecologic Oncology, 190:S6–S6. Elsevier BV, 2024. https://doi.org/10.1016/j.ygyno.2024.07.016.

Mirza M, Ghamande S, Hanker L, Black D, Raascou-Jensen N, Gilbert L, et al. Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. In: Gynecologic Oncology. Elsevier BV; 2024. p. S6–S6.

Mirza, Mansoor, et al. “Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.” Gynecologic Oncology, vol. 190, Elsevier BV, 2024, pp. S6–S6. Crossref, doi:10.1016/j.ygyno.2024.07.016.

Mirza M, Ghamande S, Hanker L, Black D, Raascou-Jensen N, Gilbert L, Oaknin A, Secord AA, Savarese A, Holloway R, Kristeleit R, Buscema J, Boere I, Sharma S, Gennigens C, Ghatage P, Yablonski K, Stevens S, Trukhan H, Powell M. Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Gynecologic Oncology. Elsevier BV; 2024. p. S6–S6.